CJC-1295 vs Ipamorelin

Published September 2026 · Patriot Labs Research Team · ~15 min read

Two secretagogues, two different receptors

The single most useful thing to hold onto is that “secretagogue” is a job description, not a chemical family. A growth-hormone secretagogue is simply any compound studied for its ability to prompt the pituitary’s somatotroph cells to release growth hormone. Two molecules can share that job and otherwise have almost nothing in common — and CJC-1295 and Ipamorelin are the textbook illustration. They approach the same cell from two different doors.

CJC-1295 is an analog of growth-hormone-releasing hormone (GHRH), the hypothalamic signal that normally tells the pituitary to make and release growth hormone. It binds the GHRH receptor. Ipamorelin is something else entirely: a short peptide that imitates ghrelin, the stomach-derived “hunger” hormone that also happens to be a potent growth-hormone signal, and it binds the separate ghrelin receptor, known formally as GHS-R1a. Because the two receptors sit on the same somatotroph and feed into different internal machinery, the compounds are not rivals doing the same thing by different routes so much as two halves of a natural control system — which is exactly why the literature so often puts them together. For the broader map of this compound class, the site’s overview of what peptides are is the natural starting point, and the two dedicated explainers on CJC-1295 and Ipamorelin go deeper on each molecule than a side-by-side can.

What each molecule actually is

Put the two structures next to each other and the mismatch in scale is the first thing you notice. Ipamorelin is a pentapeptide — just five residues — with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂, where Aib is the non-natural amino acid aminoisobutyric acid and D-2-Nal is a D-form naphthylalanine.¹ Its molecular formula is C₃₈H₄₉N₉O₅ and its molecular weight is about 711.9 daltons (CAS 170851-70-4).⁴ The presence of D-form and non-natural residues is deliberate: they make the little peptide far harder for ordinary peptidases to chew through than a chain of five standard L-amino acids would be.

CJC-1295 is, by contrast, a 29-residue peptide — roughly six times the length — because it is a copy of the first 29 amino acids of GHRH, the biologically active fragment also called GRF(1-29). (That same native 1-29 fragment, unmodified, is the molecule sold under the name sermorelin.) On its own, native GRF(1-29) is fragile, so CJC-1295’s backbone carries four amino-acid substitutions designed to armour it against the enzymes and chemistry that would otherwise degrade it. In its long-acting form it also carries an extra chemical group called a DAC, which is where the naming gets complicated — the next section untangles that. In the DAC form the molecular formula is reported as C₁₆₅H₂₆₉N₄₇O₄₆ with a molecular weight near 3,647 daltons (CAS 863288-34-0); the bare modified peptide without the DAC is about 3,368 daltons (formula C₁₅₂H₂₅₂N₄₄O₄₂).³ So one of these compounds is a small, rugged fragment and the other is a full-length hormone analog with an albumin-grabbing tail — a difference that governs almost everything else about how they behave and how a laboratory handles them.

The CJC-1295 naming tangle: with DAC, without DAC, mod GRF 1-29

No comparison involving CJC-1295 is honest without addressing the names, because the market uses several of them loosely and they do not all mean the same molecule. The confusion is worth clearing up precisely.

Start with the backbone. Native GHRH(1-29) is modified at four positions to produce a more durable peptide: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27.³ Each substitution defends a specific weakness. The D-alanine at position 2 blocks cleavage by the enzyme dipeptidyl peptidase-IV (DPP-IV), which otherwise clips native GHRH almost immediately; the glutamine at position 8 removes an asparagine prone to deamidation and rearrangement; the alanine at position 15 is associated with improved bioactivity; and the leucine at position 27 replaces a methionine that is vulnerable to oxidation. This tetrasubstituted peptide is what the research-peptide world usually calls “CJC-1295 without DAC,” and it is more accurately named modified GRF(1-29) or mod GRF 1-29. On its own it has a short laboratory half-life, on the order of thirty minutes.³

Now add the DAC. DAC stands for Drug Affinity Complex, a bioconjugation strategy developed by the biotechnology company ConjuChem. A maleimidopropionyl group, carried on an added lysine, is attached to the peptide; after subcutaneous injection this maleimide reacts with a free cysteine (Cys34) on circulating serum albumin, forming an irreversible covalent thioether bond.^2,3 Bound to the enormous, long-lived albumin molecule, the peptide is shielded from enzymatic breakdown and from being filtered out by the kidney, which stretches its reported half-life from thirty minutes to roughly six to eight days. The peptide that carries this add-on is CJC-1295 proper — the molecule studied by Teichman and colleagues — and to distinguish it from the bare version people write “CJC-1295 with DAC.” The general strategy is covered in the site’s explainer on what DAC means in peptides, which is worth reading alongside this comparison because the with-DAC/without-DAC distinction changes the pharmacology far more than most naming differences do. Ipamorelin, for its part, has no such variants: it is one defined pentapeptide with a half-life of roughly two hours, and there is no “Ipamorelin with DAC.”³

Two receptors, two intracellular pathways

This is the heart of the comparison, and it is genuinely elegant biology. Growth-hormone release from the pituitary is governed by a push-and-pull system: GHRH pushes (it stimulates release), somatostatin pulls back (it inhibits release), and ghrelin acts as a third input that both pushes and, importantly, blunts the pull. CJC-1295 and Ipamorelin each plug into a different part of that system.

CJC-1295, the GHRH analog, binds the GHRH receptor on the somatotroph. That receptor is a classic G-protein-coupled receptor that couples to the G_s protein, activating adenylyl cyclase, raising intracellular cyclic AMP (cAMP), and switching on protein kinase A. In research models this pathway drives the synthesis of growth hormone and increases the amplitude of the pulses the cell releases — it is, in effect, the “make more and release more” signal.

Ipamorelin, the ghrelin mimetic, binds the ghrelin receptor (GHS-R1a) — the receptor the 1998 discovery paper described, before ghrelin itself had been identified, as a “GHRP-like receptor.”¹ That receptor couples to a different G protein, G_q/11, activating phospholipase C and raising intracellular calcium through the IP₃ pathway. In the intact animal it does something the GHRH arm cannot: it acts to functionally oppose somatostatin, the inhibitory brake, and it helps initiate a growth-hormone pulse.⁵ So where the GHRH signal sets the size of the release, the ghrelin-receptor signal helps trigger it and removes a brake on it. Two receptors, two G proteins, two second-messenger systems — cAMP on one side, calcium on the other — converging on the same cell. A useful contrast within the catalogue is Tesamorelin, which like CJC-1295 is a GHRH analog and therefore works through the same GHRH-receptor door; Ipamorelin is the outlier of the three precisely because it uses the ghrelin door instead.

Different labs, different decades

The two molecules also come from different corners of pharmaceutical history, which reinforces how independent they are. Ipamorelin was developed in the late 1990s by researchers at Novo Nordisk and reported in a now-classic 1998 paper in the European Journal of Endocrinology titled, plainly, “Ipamorelin, the first selective growth hormone secretagogue.”¹ The word that mattered in that title was selective. Earlier growth-hormone-releasing peptides in the same family — GHRP-6 and GHRP-2 — released growth hormone but also nudged up other pituitary outputs such as ACTH and cortisol. Ipamorelin was notable because, in the reported models, it released growth hormone with a selectivity resembling GHRH itself: it did not raise ACTH or cortisol meaningfully even at doses far above those needed for its growth-hormone effect, and it left prolactin, FSH, LH and TSH essentially untouched.¹ That clean profile is the single fact most responsible for Ipamorelin’s durability as a research tool.

CJC-1295 came out of a different lineage: the DAC bioconjugation platform built by ConjuChem Biotechnologies in the 2000s, aimed at the general problem of making short-lived peptides last. The landmark human pharmacology report is Teichman and colleagues, 2006, in the Journal of Clinical Endocrinology & Metabolism, which studied single subcutaneous injections of CJC-1295 in healthy adults and documented the striking result that a single dose could sustain elevated insulin-like growth factor I (IGF-I) for days, with an estimated terminal half-life of roughly 5.8 to 8.1 days.² One molecule, in other words, was born from an endocrinology question about selectivity, the other from a chemistry question about duration — and they happen to complement each other because of it.

Side by side

The contrasts are easiest to read in a single view. The table below sets the two molecules against each other on the properties that actually distinguish them.

The research record

Both peptides have a real but bounded scientific literature, and the shapes of the two records differ. The Ipamorelin record is anchored by that 1998 characterization and the body of receptor and animal work around the growth-hormone-releasing-peptide family: primary rat pituitary-cell assays, anesthetized-rat studies, and conscious-swine models established its potency and, above all, its selectivity relative to GHRP-6.¹ It was subsequently investigated in early clinical settings for unrelated questions such as post-operative gut motility, but it was not carried through to approval as a marketed growth-hormone drug — a point the honest-limits section returns to.

The CJC-1295 record leans on the pharmacology of the DAC platform, with the 2006 Teichman study as its most-cited human data point: single subcutaneous doses produced a sustained rise in IGF-I lasting several days and a multi-day half-life, and the injections were reported as generally well tolerated in that study.² Around both molecules sits a third literature that is really about the system rather than either compound — the work on how GHRH, ghrelin and somatostatin interact to shape pulsatile growth-hormone release, which is what makes the pairing of a GHRH analog with a ghrelin-receptor agonist scientifically coherent.⁵ The table summarizes what that combined record does and does not establish.

Why the two are studied as a blend

All of the above finally explains the hyphen. The reason a CJC-1295 / Ipamorelin preparation is such a common object of study is not marketing convenience; it is the pharmacology of the growth-hormone axis. The two compounds engage non-overlapping receptors and drive non-overlapping second-messenger systems — cAMP on the GHRH side, calcium on the ghrelin side — and the ghrelin arm additionally works against somatostatin, the inhibitory brake that a GHRH signal alone cannot lift.⁵ When two inputs act on the same cell through independent machinery, their combined effect can be greater than the sum of the parts, and that supra-additive growth-hormone response is exactly what the combination literature reports in research models. One arm makes the pituitary want to release more; the other helps pull the trigger and holds off the brake.

That is the scientific logic behind combined GHRH-plus-secretagogue preparations, and it is a specific instance of a general principle the site covers in its guide to why peptides are blended: compounds are combined when their mechanisms complement one another, not simply to put more actives in a vial. It bears repeating that this is a description of mechanism as studied in the laboratory. That two research peptides show a cooperative effect on growth-hormone release in a cell or animal model is a fact about receptor biology; it is not a claim about results in any person, and nothing here should be read as one.

Bench practice: characterizing two very different peptides

The scale difference between the two molecules shows up again at the analytical bench, and it is a good illustration of why third-party testing is not one-size-fits-all. Ipamorelin, at about 712 daltons, is a small, well-behaved peptide: reversed-phase HPLC resolves it cleanly and reports purity by peak area, and mass spectrometry confirms its identity against a single, exact expected mass. A short peptide with a defined sequence is about as tidy as identity testing gets.

CJC-1295 is a larger and more interesting analytical target. At roughly 3.6 kilodaltons it is still well within reach of the same techniques — HPLC for purity, mass spectrometry for the expected mass — but there is a subtlety worth flagging: the DAC’s defining behaviour, the covalent bond to serum albumin, is an in-vivo event that happens only after injection into a living system. In the vial there is no albumin, so what a certificate of analysis characterizes is the unconjugated peptide with its intact maleimide group, not the albumin conjugate; the maleimide’s reactivity is also a reason handling and storage matter for this particular molecule. For both peptides, the meaningful questions a buyer should ask are the same ones the site’s guide to reading a certificate of analysis lays out: does an HPLC trace support the stated purity, does a mass-spec reading confirm the right molecule, and is the certificate lot-specific? Both are supplied as lyophilised (freeze-dried) solids and follow the general handling rules in the site’s storage guide — kept cool, sealed, dry and out of light as a powder, and treated as far more fragile once reconstituted. None of that is a use instruction; it is the analytical hygiene that lets a laboratory trust the label.

What the evidence does not establish

A comparison like this is only as trustworthy as the boundary it draws around itself, so the boundary should be explicit. Everything above is structure, receptor mechanism, and the published research record. None of it describes what either peptide does for a person, and none of it is a protocol. The mechanistic picture — two receptors, two pathways, a cooperative effect on growth-hormone release in models — is a statement about cell and animal biology and, for CJC-1295, a small human pharmacology study, not a statement about outcomes for anyone.

Two limits deserve naming directly. First, the human evidence is thin for both. CJC-1295’s most-cited clinical data come from a single small study in healthy adults measuring hormone levels, not long-term results; Ipamorelin’s human work was early-stage and pursued for indications unrelated to the uses it is popularly associated with, and it was never approved as a marketed growth-hormone product. Neither is an approved drug for general use. Second, the widely repeated framing of these peptides in terms of body composition, recovery or ageing runs well ahead of what the controlled literature actually supports; a documented effect on a hormone level in a study is not the same as a demonstrated outcome, and the two should never be conflated. For readers placing these molecules in context, the individual explainers on CJC-1295 and Ipamorelin, the DAC primer, and the guide to why peptides are blended are the honest reference points. The accurate summary is simple: CJC-1295 and Ipamorelin are two mechanistically distinct growth-hormone secretagogues, studied together because their receptor pathways complement one another, and offered here strictly as research materials characterized for identity and purity — and on no other footing.

Frequently asked questions

What is the main difference between CJC-1295 and Ipamorelin?

They belong to two different families of growth-hormone secretagogue and act at two different receptors. CJC-1295 is a long-acting analog of growth-hormone-releasing hormone (GHRH) that engages the GHRH receptor on pituitary somatotroph cells. Ipamorelin is a short synthetic pentapeptide that mimics ghrelin and engages the separate ghrelin receptor (GHS-R1a), the target the 1998 discovery paper called a “GHRP-like receptor.” CJC-1295 is a 29-residue peptide of roughly 3,647 daltons in its DAC form; Ipamorelin is a five-residue peptide of about 712 daltons. Because the two act through different receptors and different intracellular pathways, the research literature often studies them together rather than as substitutes for one another.

Why are CJC-1295 and Ipamorelin studied together as a blend?

Because their mechanisms are complementary rather than redundant. In pituitary research models a GHRH analog such as CJC-1295 acts through the GHRH receptor and the cyclic-AMP pathway, while a ghrelin-mimetic secretagogue such as Ipamorelin acts through the ghrelin receptor and the calcium pathway and also functionally opposes somatostatin, the brake on growth-hormone release. Combining a GHRH signal with a ghrelin-receptor signal has been reported to produce a greater growth-hormone response in laboratory and animal models than either class alone, which is the scientific rationale behind combined GHRH-plus-secretagogue preparations. This describes the pharmacology observed in research; it is not a statement about use in humans.

What is the difference between CJC-1295 with DAC and CJC-1295 without DAC (modified GRF 1-29)?

They share the same 29-residue peptide backbone but differ by one add-on. Modified GRF 1-29 is the tetrasubstituted GHRH(1-29) peptide on its own, with a laboratory half-life on the order of thirty minutes; it is what the market usually means by “CJC-1295 without DAC.” CJC-1295 proper carries an additional Drug Affinity Complex (DAC): a maleimidopropionyl-lysine group that, after subcutaneous injection, reacts with a cysteine on circulating serum albumin to form a long-lived conjugate, extending the reported half-life to roughly six to eight days. In other words, “without DAC” is the bare peptide and “with DAC” is the albumin-binding, long-acting version studied by Teichman and colleagues in 2006. The DAC explainer covers the chemistry in full.

Is CJC-1295 or Ipamorelin a steroid?

No. Neither is a steroid. Both are peptides, chains of amino acids, and they belong to a class called growth-hormone secretagogues, meaning that in research models they act on pituitary cells that produce growth hormone rather than being a hormone themselves. A steroid is a small lipid-based molecule with a completely different four-ring structure and a different mechanism. CJC-1295 and Ipamorelin are studied as signaling peptides that engage cell-surface receptors, which is a separate pharmacology entirely.

Are CJC-1295 and Ipamorelin intended for human use?

No. CJC-1295 and Ipamorelin supplied by Patriot Labs are sold strictly for in-vitro research and laboratory use only. They are not for human or veterinary consumption, and nothing in this guide describes how to administer either one. Everything here concerns their chemistry, their receptor mechanisms as reported in the scientific literature, and how a laboratory characterizes them for identity and purity. Neither peptide is an approved drug for general use, and the research record described in this guide is not a claim about what either does for any person. For the practical side of sourcing verified material, see the COA guide and the guide on storing research peptides.

References

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes peptide chemistry, receptor mechanisms and published research in general terms; it is not medical advice, does not describe how to use any product, and the references cited do not constitute a product claim.